Trial reportSurgical endoscopy2026
Efficacy of Sapylin in endoscopic thyroid cancer surgery: a double-blind, randomized, controlled trial.
Trial report in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePostoperative exudation after thyroidectomy can compromise healing. Although Sapylin (Group A Streptococcus pyogenes) promotes wound repair, its efficacy and safety in endoscopic thyroid cancer surgery remain unclear. This randomized controlled trial evaluated Sapylin's impact on postoperative drainage and complications.
methodsNinety-two patients were randomized (1:1) to receive 10 KE Sapylin in 20 ml saline (treatment group) or saline alone (control group) via the drainage tube. Endpoints included drainage volume, inflammatory markers, and assessment of short-term and long-term complications, specifically vocal function.
resultsThe treatment group showed significantly lower drainage volumes on Day 1 (P = 0.026), Day 2 (P = 0.014), and in total (P = 0.009). Inflammatory markers were transiently elevated in the treatment group (P < 0.01) but normalized rapidly. Notably, the incidence of hoarseness was significantly higher in the treatment group (16 vs. 6 cases, P = 0.015). Crucially, long-term follow-up confirmed that all cases of hoarseness were transient. All affected patients achieved complete recovery of vocal cord mobility, and no cases of permanent vocal cord paralysis were observed.
conclusionSapylin significantly reduces postoperative drainage volume following endoscopic radical thyroidectomy. However, its application is associated with a systemic inflammatory response and an increased risk of transient postoperative hoarseness. Although this nerve dysfunction is reversible, given the potential for neural irritation, its application should be restricted or approached with extreme caution, carefully weighing the benefits of drainage reduction against the risk of transient hoarseness. TRAIL REGISTRATION: This study was registered with the Chinese Clinical Trial Registry (accessible by logging in at https://www.chictr.org.cn/ ), registration number ChiCTR2500103444.
Indexed as
Identifiers
42377525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.